Loncastuximab tesirine + Rituximab

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Follicular Lymphoma

Conditions

Follicular Lymphoma

Trial Timeline

Feb 11, 2022 → Aug 1, 2030

NCT ID

NCT04998669

About Loncastuximab tesirine + Rituximab

Loncastuximab tesirine + Rituximab is a phase 2 stage product being developed by ADC Therapeutics for Follicular Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04998669. Target conditions include Follicular Lymphoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06788964	Phase 2	Recruiting	Aug 25, 2025	Mar 1, 2030	Relapsed or Refractory Large B-cell Lymphoma
NCT05144009	Phase 2	Terminated	Jun 21, 2022	Jan 22, 2024	Diffuse Large B-cell Lymphoma
NCT04998669	Phase 2	Recruiting	Feb 11, 2022	Aug 1, 2030	Follicular Lymphoma

Competing Products

20 competing products in Follicular Lymphoma

See all competitors

Product	Company	Stage	Hype Score
Enzastaurin	Eli Lilly	Phase 2	52
CT-P10 + Rituxan	Celltrion	Phase 3	77
Rituxan + CT-P10 + Cyclophosphamide + Vincristine + Prednisone	Celltrion	Phase 3	77
Tazemetostat	Eisai	Pre-clinical	23
Zandelisib + Rituximab + Bendamustine + CHOP	Kyowa Kirin	Phase 3	77
Pirtobrutinib + Mosunetuzumab	Eli Lilly	Phase 2	52
fludarabine + rituximab + VELCADE	Johnson & Johnson	Phase 2	52
SHR2554	Jiangsu Hengrui Medicine	Phase 2	52
Epcoritamab + Rituximab	AbbVie	Phase 2	52
Epcoritamab + Rituximab + Lenalidomide	AbbVie	Phase 3	77
Ibrutinib + Venetoclax	AbbVie	Phase 1/2	41
Epcoritamab + Prednisone + Rituximab + Lenalidomide + Doxorubicin + Vincristine + Cyclophosphamide + Obinutuzumab + Bendamustine	AbbVie	Phase 3	77
Venetoclax + Bendamustine + Rituximab	AbbVie	Phase 2	52
Acalabrutinib + Obinutuzumab	AstraZeneca	Phase 2	52
Surovatamig + R-CHOP + R-CVP + BR	AstraZeneca	Phase 3	77
Gonal-F (Follitropin alfa)	Merck	Pre-clinical	23
Eltrombopag and Vorinostat	Merck	Phase 2	52
Recombinant-follicle stimulating hormone (r-FSH)	Merck	Pre-clinical	23
Acalabrutinib + Pembrolizumab	Merck	Phase 1/2	41
Rituximab + Autologous dendritic cells + GM-CSF + Pembrolizumab	Merck	Phase 2	52

Other Products from ADC Therapeutics

Loncastuximab Tesirine + Rituximab + Gemcitabine + OxaliplatinPhase 3

Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/KgPhase 2

Loncastuximab Tesirine + RituximabPhase 2

Loncastuximab tesirinePhase 2

Loncastuximab Tesirine + RituximabPhase 2